Infliximab in the treatment of rheumatoid arthritis

Journal of Clinical Excellence

Volumn 3, Issue 4, 2001, Pages 211-214

  Winning, Alison ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; MONOTHERAPY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYMPTOM;

EID: 0035689001     PISSN: 14659883     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Secondary health service care and second line drug costs of early inflammatory polyarthritis in Norfolk, UK
2. The costs of rheumatoid arthritis an international long-term view
3. The cost of rheumatoid arthritis
4. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?
5. Infliximab and etanercept for treating rheumatoid arthritis (protocol)
6. Methotrexate in rheumatoid arthritis: A five year prospective study
7. How Canadian and US rheumatologists treat moderate or agressive rheumatoid arthritis: A survey
8. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
9. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three medications
10. How do the biologics fit into the current DMARD armamentarium?
11. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
12. WHO Collaboratinrg Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis
13. The ARA: 1987 revised criteria for the classification of rheumatoid arthritis
14. Modified Disease Activity Scores that include twenty-eight joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
15. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis
16. Consensus recommendations for the assessment and treatment of rheumatoid arthritis
17. A summary of clinical trials in rheumatoid arthritis using infliximab, an anti-alpha treatment
18. Infliximab: A review of its use in the management of rheumatoid arthritis
19. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: The clinical experience with infliximab
20. Treatment options for rheumatoid arthritis: Celecoxib, leflunomide, etanercept, infliximab
21. Pharmacotherapy of rheumatoid arthritis: An overview
22. Rational use of new and existing disease modifying agents in rheumatoid arthritis
23. TNF blockade in the treatment of rheumatoid arthritis: Infliximab versus etanercept
24. Anti-tumour necrosis factor therapies
25. Old and new drugs used in rheumatoid arthritis: A historical perspective. Part 2: The newer drugs and drug strategies
26. Anti-cytokine treatment for rheumatoid arthritis
27. New disease modifying agents in adult rheumatoid arthritis
28. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p. 75) - Fc fusion protein
29. The therapeutic effects of an engineered human anti-tumour necrosis factor an antibody (CDP571) in rheumatoid arthritis
30. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (Ca2) versus placebo in rheumatoid arthritis
31. Infliximab at different doses was effective for rheumatoid arthritis after unsuccessful methotrexate treatment
32. Infliximab and methotrexate in the treatment of rheumatoid arthritis
33. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
34. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
35. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
36. Successful treatment of ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
37. Review article: Safety of infliximab in clinical trials